• This record comes from PubMed

Synthesis and biological activity of olomoucine II

. 2002 Nov 18 ; 12 (22) : 3283-6.

Language English Country England, Great Britain Media print

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Based on our previous experiences with synthesis of purines, novel 2,6,9-trisubstituted purine derivatives were prepared and assayed for the ability to inhibit CDK1/cyclin B kinase. One of newly synthesized compounds designated as olomoucine II, 6-[(2-hydroxybenzyl)amino]-2-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine, displays 10 times higher inhibitory activity than roscovitine, potent and specific CDK1 inhibitor. Olomoucine II in vitro cytotoxic activity exceeds purvalanol A, the most potent CDK inhibitor, as it kills the CEM cells with IC(50) value of 3.0 microM.

References provided by Crossref.org

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...